Strauss A L, Coe F L, Deutsch L, Parks J H
Am J Med. 1982 Jan;72(1):17-24. doi: 10.1016/0002-9343(82)90566-6.
We evaluated 522 patients with idiopathic, recurrent calcium nephrolithiasis using a comprehensive clinical and laboratory protocol, and obtained additional laboratory measurements during their subsequent years of treatment in our program. In 57 patients, a new calcium stone ultimately formed during treatment (relapse), whereas 189 others have been free of recurrence during at least two years (average 4.3 +/- 2.2 [SD] years) of follow-up. Compared with the patients who remained stone-free, the patients with relapse (1) had a shorter interval between the time they entered our program and the time their last recurrent, pretreatment stone formed; (2) excreted more calcium *in mg/kg of body weight pr 24 hours) in their urine during treatment (2.79 +/- 1.08 versus 2.39 +/- 0.98 [SD] for relapse and stone-free); and (3) increased their urine volume less during treatment compared with pretreatment values (delta in liters per 24 hours was -0.02 +/- 0.48 versus 0.23 +/- 0.54 for relapse and stone-free). The two groups were otherwise the same. All comparisons used only data obtained prior to relapse. A discriminant function using only these three characteristics correctly identified 72 percent of patients with relapse and 67 percent of those who remained stone-free.
我们采用全面的临床和实验室方案对522例特发性复发性钙肾结石患者进行了评估,并在他们后续接受我们治疗方案的几年中获取了更多实验室测量数据。在57例患者中,治疗期间最终形成了新的钙结石(复发),而其他189例患者在至少两年(平均4.3±2.2[标准差]年)的随访中未复发。与结石未复发的患者相比,复发患者:(1)从进入我们的治疗方案到最后一次复发的治疗前结石形成的时间间隔较短;(2)治疗期间尿中钙排泄量(每24小时毫克/千克体重)更多(复发组和结石未复发组分别为2.79±1.08和2.39±0.98[标准差]);(3)与治疗前相比,治疗期间尿量增加较少(每24小时升的变化量复发组为-0.02±0.48,结石未复发组为0.23±0.54)。两组在其他方面相同。所有比较仅使用复发前获得的数据。仅使用这三个特征的判别函数正确识别出72%的复发患者和67%的结石未复发患者。